

Supporting Information

Carén et al. 10.1073/pnas.0910684107






Fig. S1. Representative chromatograms of the SNP whole genomic profile groups studied. From top to bottom, the *MYCN*-amplification group (red arrow indicate the highly amplified “off-chart” signal), the 11q-deletion group, the 17q-gain group, the other segmental aberrations group, the numerical-only group, the flat profile group, and normal controls. All of these cases involve tumors from male patients compared with normal female controls, which explains the low X signal. Chromosomes with segmental aberrations are denoted by a solid arrowhead, whereas chromosomes with numerical deviations are denoted by open arrowheads. See *Materials and Methods* for definitions of the genomics profile groups.



Chromosomal breaks
in MYCN cases



Chromosomal breaks
in 11q-del cases

Fig. S2. Distribution of chromosomal breaks in *MYCN*-amplified tumors (*Top*) and 11q-deleted tumors (*Bottom*). Horizontal lines indicate the different chromosomes. The dark-gray sections on each line indicate centromeres and heterochromatic regions with low numbers of SNPs on the array. Numbers to the right indicate the length of the chromosomes (in Mb).




Fig. S3. Representative SNP array profiles for chromosome 11 in a number of 11q-deletion cases and the positions of the breakpoints relative to the *H2AFX*. One case showed a small rearrangement in the *H2AFX* region only (open arrow).




Fig. S4. Boxplots showing that (A) 11q-deleted NB tumors have significantly lower *H2AFX* expression compared with *MYCN*-amplified tumors with intact chromosomes 11 and (B) 11q-deleted NB cell lines have lower *H2AFX* expression compared with cell lines with intact 11 chromosomes. The ordinate represents *H2AFX* expression on a log-10 scale, and the level of significance is indicated in the lower left corner of the boxplots.

Table S1. Data on stage, outcome and genomic profile group (same order as in Fig. 1)

Tumor ID	INSS stage*	INRG stage [†]	Outcome [‡]	Genomic profile group
1	4	M	NED	MNA
2	4	M	DOD	MNA
3	4	M	NED	MNA
4	4	M	NED	MNA
5	3	L	NED	MNA
6	1	L	DOD	MNA
7	4	M	DOD	MNA
8	4S	MS	DOD	MNA
9	4	M	DOD	MNA
10	4	M	DOD	MNA
11	4	M	DOD	MNA
12	4	M	DOD	MNA
13	3	L	DOD	MNA
14	4	M	NED	MNA
15	4	M	DOD	MNA
16	4	M	DOD	MNA
17	4	M	DOD	MNA
18	4	M	DOD	MNA
19	3	L	DOD	MNA
20	4S	MS	DOD	MNA
21	3	L	NED	MNA
22	4	M	DOD	MNA
23	4	M	NED	MNA
24	4	M	DOD	MNA
25	3	L	NED	MNA
26	4	M	NED	MNA
27	4	M	DOD	MNA
28	4	M	NED	MNA
29	4	M	NED	MNA
30	3	L	NED	MNA
31	3	L	NED	MNA
32	4	M	NED	MNA
33	4	M	NED	MNA
34	4	M	DOD	MNA
35	4	M	NED	MNA
36	4	M	NED	MNA
37	4	M	DOD	MNA
38	3	L	DOD	MNA + 11q-del
39	4	M	DOD	11q-del
40	4	M	DOD	11q-del
41	4	M	NED	11q-del
42	2	L	DOD	11q-del
43	4	M	DOD	11q-del
44	4	M	DOD	11q-del
45	3	L	DOD	11q-del
46	4	M	DOD	11q-del
47	3	L	DOD	11q-del
48	4	M	DOD	11q-del
49	4	M	NED	11q-del
50	4	M	DOD	11q-del
51	4	M	NED	11q-del
52	4	M	NED	11q-del
53	4	M	DOD	11q-del
54	4	M	DOD	11q-del
55	4	M	NED	11q-del
56	3	M	DOD	11q-del
57	3	L	NED	11q-del
58	4	M	NED	11q-del
59	1	L	NED	11q-del
60	3	L	NED	17q-gain (without MNA or 11q-del)
61	2	L	NED	17q-gain (without MNA or 11q-del)
62	1	L	NED	17q-gain (without MNA or 11q-del)
63	4	M	NED	17q-gain (without MNA or 11q-del)

Table S1. Cont.

Tumor ID	INSS stage*	INRG stage [†]	Outcome [‡]	Genomic profile group
64	4	M	NED	17q-gain (without MNA or 11q-del)
65	2	L	NED	17q-gain (without MNA or 11q-del)
66	3	L	AWD	17q-gain (without MNA or 11q-del)
67	4	M	DOD	17q-gain (without MNA or 11q-del)
68	4	M	NED	17q-gain (without MNA or 11q-del)
69	4	M	DOD	17q-gain (without MNA or 11q-del)
70	4	M	NED	17q-gain (without MNA or 11q-del)
71	2	L	DOD	17q-gain (without MNA or 11q-del)
72	4	M	DOD	17q-gain (without MNA or 11q-del)
73	2	L	NED	17q-gain (without MNA or 11q-del)
74	4	M	NED	Other segmental
75	4	M	NED	Other segmental
76	3	L	NED	Other segmental
77	1	L	NED	Other segmental
78	1	L	NED	Other segmental
79	2	L	NED	Other segmental
80	1	L	NED	Other segmental
81	3	L	NED	Other segmental
82	2	L	NED	Other segmental
83	2	L	NED	Other segmental
84	3	L	NED	Other segmental
85	2	L	NED	Other segmental
86	2	L	NED	Other segmental
87	2	L	NED	Other segmental
88	1	L	NED	Num only
89	4S	MS	NED	Num only
90	1	L	NED	Num only
91	3	L	NED	Num only
92	1	L	NED	Num only
93	2	L	NED	Num only
94	2	L	NED	Num only
95	3	L	NED	Num only
96	1	L	NED	Num only
97	3	L	NED	Num only
98	2	L	NED	Num only
99	1	L	NED	Num only
100	3	L	NED	Num only
101	1	L	NED	Num only
102	1	L	NED	Num only
103	2	L	NED	Num only
104	1	L	NED	Num only
105	4S	MS	NED	Num only
106	2	L	DOD	Num only
107	4S	MS	NED	Num only
108	4S	MS	NED	Num only
109	3	L	DSC	Num only
110	2	L	NED	Num only
111	2	L	NED	Num only
112	1	L	NED	Num only
113	4S	MS	NED	Num only
114	1	L	NED	Num only
115	2	L	NED	Num only
116	1	L	NED	Num only
117	1	L	NED	Num only
118	4	M	DOD	Num only
119	3	L	NED	Num only
120	1	L	NED	Num only
121	1	L	NED	Num only
122	1	L	NED	Num only
123	4	M	DOD	Num only
124	2	L	NED	Num only
125	2	L	NED	Num only

Table S1. Cont.

Tumor ID	INSS stage*	INRG stage [†]	Outcome [‡]	Genomic profile group
126	1	L	NED	Num only
127	3	L	NED	Num only
128	3	L	NED	Num only
129	3	L	NED	Num only
130	4S	MS	NED	Num only
131	2	L	NED	Num only
132	1	L	NED	Num only
133	2	L	NED	Num only
134	1	L	NED	Num only

*Neuroblastoma stage according to INSS (reference 24).

[†]Neuroblastoma stage according to INRG (reference 25). Due to lack of imaging data L1 and L2 stages are denoted L.

[‡]Outcome: NED = No evidence of disease, AWD = alive with disease, DOD = Dead of disease, DSC = dead of surgical complications.

1. Brodeur GM, et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. *J Clin Oncol* 11:1466–1477.
2. Monclair T, et al., INRG Task Force (2009) The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. *J Clin Oncol* 27:298–303.